1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
Diabetic Retinopathy (DR) – Epidemiology Forecast—2030

Diabetic Retinopathy (DR) – Epidemiology Forecast—2030

  • December 2020
  • 95 pages
  • ID: 5993617
  • Format: PDF
  • Delve Insight

Summary

Table of Contents

‘Diabetic Retinopathy (DR) – Epidemiology Forecast—2030’ report delivers an in-depth understanding of the Diabetic Retinopathy, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Diabetic Retinopathy Disease Understanding
Diabetic retinopathy (DR) is a common and specific microvascular complication of diabetes and remains the leading cause of preventable blindness in working-aged people. It is identified in a third of people with diabetes and is associated with increased risk of life-threatening systemic vascular complications, including stroke, coronary heart disease, and heart failure. In the USA, an estimated 40% (8% for vision-threatening retinopathy) of people with type 2 diabetes and 86% (42%) with type 1 diabetes have diabetic retinopathy.
Epidemiological, clinical, and laboratory studies have increased the understanding of the pathophysiological changes of diabetic retinopathy, culminating recently in new treatment options for diabetic macular edema. Furthermore, screening programs have enabled early diagnosis and prompt treatment of sight-threatening retinopathy. Despite these advances in the field, the prevalence of diabetic retinopathy remains high at 40%. Globally, there are approximately 93 million people with diabetic retinopathy, 17 million with proliferative retinopathy, 21 million with diabetic macular edema, and 28 million with sight-threatening retinopathy, making diabetic retinopathy a significant global public health and economic problem.

Diabetic Retinopathy Epidemiology
The Diabetic Retinopathy epidemiology division provides insights about the historical and current patient pool, along with the forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings
The total prevalent cases of Diabetic Retinopathy patients are increasing in 7MM during the study period, i.e. 2017–2030.
The disease epidemiology covered in the report provides historical as well as forecasted Diabetic Retinopathy symptoms epidemiology segmented as the Total Prevalent cases of Diabetic Retinopathy, Gender-specific cases of Diabetic Retinopathy, Age-specific cases of Diabetic Retinopathy, and Severity-specific cases of Diabetic Retinopathy. The report includes the prevalent scenario of Diabetic Retinopathy symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Diabetic Retinopathy Epidemiology
The epidemiology segment also provides the Diabetic Retinopathy epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The total diagnosed cases of Diabetic Retinopathy associated in 7MM countries were 16,965,550 in 2017.
• As per the estimates, the United States has the largest diagnosed population of Diabetic Retinopathy.
• Among the EU5 countries, Germany had the highest diagnosed cases of Diabetic Retinopathy, followed by Italy. On the other hand, the UK had the lowest prevalent cases with 831,286 cases in 2017.

Scope of the Report
• The Diabetic Retinopathy report covers a detailed overview explaining its causes, symptoms, and classification, pathophysiology, diagnosis, and treatment patterns.
• The Diabetic Retinopathy Epidemiology Report and Model provide an overview of the risk factors and global trends of Diabetic Retinopathy in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
• The report provides insight into the historical and forecasted patient pool of Diabetic Retinopathy in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.
• The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
• The report assesses the disease risk and burden and highlights the unmet needs of Diabetic Retinopathy.
• The report provides the segmentation of the Diabetic Retinopathy epidemiology by Diagnosed Cases of Diabetic Retinopathy in 7MM.
• The report provides the segmentation of the Diabetic Retinopathy epidemiology by Gender-Specific Prevalent Cases of Diabetic Retinopathy in 7MM.
• The report provides the segmentation of the Diabetic Retinopathy epidemiology by Age-Specific Prevalent Cases of Diabetic Retinopathy in 7MM.
• The report provides the segmentation of the Diabetic Retinopathy epidemiology by Severity-Specific Prevalent Cases of Diabetic Retinopathy in 7MM.

Report Highlights

• 11-Year Forecast of Diabetic Retinopathy epidemiology
• 7MM Coverage
• Total Diagnosed Cases of Diabetic Retinopathy
• Prevalent Cases according to segmentation: Gender-specific cases of Diabetic Retinopathy
• Prevalent Cases according to segmentation: Age-specific cases of Diabetic Retinopathy
• Prevalent Cases according to segmentation: Severity-specific cases of Diabetic Retinopathy

KOL- Views
We interview KOLs, and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered
• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Diabetic Retinopathy?
• What are the key findings pertaining to the Diabetic Retinopathy epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017–2030)?
• What would be the total number of patients of Diabetic Retinopathy across the 7MM during the forecast period (2017–2030)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017–2030)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017–2030)?
• What are the disease risk, burden, and unmet needs of the Diabetic Retinopathy?
• What are the currently available treatments of Diabetic Retinopathy?

Reasons to buy
The Diabetic Retinopathy epidemiology report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the global Diabetic Retinopathy market
• Quantify patient populations in the global Diabetic Retinopathy market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Diabetic Retinopathy therapeutics in each of the markets covered
• Understand the magnitude of Diabetic Retinopathy population by its Diagnosed cases
• Understand the magnitude of Diabetic Retinopathy population by its Gender-specific cases
• Understand the magnitude of Diabetic Retinopathy population by its Age-specific cases
• Understand the magnitude of Diabetic Retinopathy population by its Severity-specific cases
• The Diabetic Retinopathy epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists
• The Diabetic Retinopathy Epidemiology Model developed is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2017–2030
Diabetic retinopathy (DR) results from high blood sugar levels, which cause damage to blood vessels in the retina. This might result in blood vessels swelling and leaking or causing a blockage in blood flow. Sometimes abnormal new blood vessels grow on the retina leading to blindness.
According to the United States National Diabetes Statistics Report 2020, 13% of the population was suffering from diabetes. The International Diabetes Federation (IDF) is an umbrella organization of over 240 national diabetes associations in 168 countries and territories. IDF is engaged in action to tackle diabetes from the local to the global level from programs at the community level to worldwide awareness and advocacy initiatives. IDF’s latest report was accessed to find the diabetes prevalence rate in the other seven major markets for patients aged 20 years or older. As diabetes prevalence rates continue to grow, globally, IDF’s 2030 diabetes rate projections were used to reflect the growing burden of diabetes.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Diabetic Retinopathy (Metabolic Disorder) - Drugs in Development, 2021

  • $ 2000
  • October 2021
  • 424 pages

Diabetic Retinopathy (Metabolic Disorder) - Drugs in Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Retinopathy - Drugs In Development, 2021, provides ...

  • United States
  • Type 2 Diabetes
  • Drug Development
  • Industry analysis
  • Pharmaceutical Registrations
  • Drug Approval

ref:plp2020

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on